Scan that makes prostate cancer cells glow could cut need for biopsies
An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following inconclusive or reassuring results from an MRI scan, new research has found.
Findings from the PRIMARY2 trial are presented today [Friday 13 March 2026] at the European Association of Urology Congress in London (EAU26).
The PSMA PET/CT scan identifies more aggressive prostate cancer cells, which are potentially harmful and may need treatment. It does this with a molecule that binds to prostate cancer ...